S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Cubist Reports Second Quarter 2014 Financial Results|
|Cubist to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)|
|Cubist’s SIVEXTRO™ (tedizolid phosphate) Approved in U.S. to Treat Serious Skin Infections—Including Those Caused by MRSA|
|Cubist’s Once-daily SIVEXTRO™ (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations|
|Cubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review|
|Cubist to Announce Second Quarter 2014 Financial Results on Tuesday, July 22, 2014|
|Cubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review|
|Cubist to Present at Morgan Stanley Global Healthcare Conference|
|Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter|
|Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Nine Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Following Complaints of Foreign Particulate Matter in Reconstituted Vials|
Click above to view more mutual fund data and stats for cbst - Cubist Pharmaceuticals Inc.